Preparation of [131I]lipiodol as a hepatoma therapeutic agent.
An isotopic exchange method was used to label lipiodol with 131I. The labelling efficiency was > 92.5%, and the radiochemical purity of [131I]lipiodol was above 98% as determined by ITLC. The influencing factors e.g. the heating temperature, reaction time, pH and storage conditions were studied and the optimum conditions were determined. In a pilot study injecting [131I]lipiodol for the treatment of hepatoma, about 70% of hepatoma patients had a response to the treatment with a reduction of alpha-fetoprotein and decrease of hepatoma sizes. The overall median survival was 9 months (range 2-17 months).